The identification of miR‐3656 as a key regulator of ESCC progression through the PI3K/AKT and Wnt/β‐catenin pathways underscores its potential as a therapeutic target, independent of its exosomal delivery mechanism. This evidence concerns the gene PIK3CG and esophageal squamous cell carcinoma.